CD38 expression	Lymphoma	CD38 expression	Lymphoma	rituximab + NKTR-255 Sensitive: C3 – Early Trials rituximab + NKTR-255 Sensitive : C3	rituximab + NKTR-255 Sensitive: C3 – Early Trials rituximab + NKTR-255 Sensitive : C3
CD20 expression	Lymphoma	CD20 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3
CD38 expression	Lymphoma	CD38 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3
CD20 expression	Lymphoma	CD20 expression	Lymphoma	NKTR-255 + Ritucad (rituximab biosimilar) Sensitive: D – Preclinical NKTR-255 + Ritucad (rituximab biosimilar) Sensitive : D	NKTR-255 + Ritucad (rituximab biosimilar) Sensitive: D – Preclinical NKTR-255 + Ritucad (rituximab biosimilar) Sensitive : D
ROR1 positive	Lung Cancer	ROR1 positive	Lung Cancer	NKTR-255 Sensitive: D – Preclinical NKTR-255 Sensitive : D	NKTR-255 Sensitive: D – Preclinical NKTR-255 Sensitive : D

avipendekin pegol (NKTR-255)

Associations
(5)